Abstract | Oxygen availability, along with the abundance of nutrients (such as glucose, glutamine, lipids and albumin), fluctuates significantly during tumour evolution and the recruitment of blood vessels, leukocytes and reactive fibroblasts to complex tumour microenvironments. As such, hypoxia and concomitant nutrient scarcity affect large gene expression programmes, signalling pathways, diverse metabolic reactions and various stress responses. This Review summarizes our current understanding of how these adaptations are integrated in hypoxic tumour cells and their role in disease progression.
Molecular oxygen (O 2 ) is an essential nutrient that serves as a key substrate for mitochondrial ATP production and numerous intracellular biochemical reactions. The maintenance of O 2 homeostasis is, therefore, essential for the survival of most prokaryotic and eukaryotic species. O 2 deprivation (hypoxia) triggers complex adaptive responses at cellular, tissue and organismal levels to match O 2 supply with metabolic and bioenergetic demand 1 . When faced with hypoxia, cells engage multiple evolutionarily conserved molecular responses, including those mediated by the hypoxia-inducible factor (HIF) transcriptional regulators, mTOR complex 1 (mTORC1), autophagy, endoplasmic reticulum (ER) stress responses, a large family of O 2 -dependent (and 2-oxoglutarate (also known as α-ketoglutarate)-dependent) dioxygenases and other O 2 -sensing mechanisms (such as reactions that introduce double bonds into long-chain fatty acids) 2 . These responses to changes in O 2 and nutrient availability promote altered metabolism, cell motility, angiogenesis, inflammation and systemic changes in erythropoiesis, respiration and cardiac function 3 and, as such, have a central role in development, physiology and diseases such as cancer. Solid tumours, in particular, develop oxygen-and nutrient-deprived microenvironments as cancer cells outgrow O 2 supply via native blood vessels and trigger aberrant angiogenic signalling that disrupts normal blood vessel recruitment 2 . When faced with hypoxic and/or ischaemic conditions cancer cells use O 2 -sensing pathways to adapt to microenvironmental stresses. Additionally, hypoxia correlates with therapeutic resistance to both cytotoxic drugs and radiotherapy 4, 5 . Here, we describe how these responses affect intracellular metabolism and the impact that altered metabolism has on the progression of solid tumours. We will also review the current state of hypoxia-targeted therapeutics and potential clinical applications for these agents.
HIFs and metabolic adaptations
The notion that HIFα stabilization under tumour hypoxia (FIG. 1) provides adaptive advantages to cancer cells by altering gene expression and metabolism has ample support 3 . However, this is almost certainly too simple, as it fails to account for differential oncogenic and tumour suppressor effects downstream of HIF expression in specific cancer types, the paucity of activating mutations in HIF in human cancers, a lack of universal concordance between patterns of HIF α-subunit (HIF1α and HIF2α) protein expression and measurable hypoxia in solid tumours and, finally, basal HIF α-subunit accumulation in many cancer cell lines under atmospheric ('normoxic') conditions. It is clear that stabilization and activation of HIF α-subunits are highly responsive to both environmental cues and genetic alterations in signalling pathways (owing to mutations in oncogene and/or tumour suppressor) that create a background context for HIF function 2, 3 . Furthermore, the traditional model places HIF atop a transcriptional programme that, in part, alters metabolic 'wiring' to support tumour cell survival, growth and proliferation. However, recent data reveal a more intricate relationship, in which meta bolic enzymes, as well as their substrates and products, reciprocally modulate HIF activity through various complex feedback mechanisms.
HIF, metabolism and mitochondrial reactive oxygen species. It is well established that increased rates of glycolysis in cancer cells and rapidly dividing normal cells in tissues with abundant O 2 (the Warburg effect) generate crucial biosynthetic intermediates required for the production of NADPH, nucleotides, amino acids, lipids and glycogen, as well as ATP and other compounds essential for cell growth and division 6 . HIFα stabilization in response to environmental cues (for example, hypoxia
Ischaemic conditions
Tissue environment in which cells are limited for oxygen and other blood-borne nutrients (such as glucose, glutamine, lipids and albumin) simultaneously, as opposed to being merely O 2 deprived or hypoxic. 
Reactive oxygen species (ROS)
.
Mitophagy
A specialized form of autophagy devoted to breakdown of mitochondria in response to certain stimuli. and redox stress) and/or alterations in oncogene signalling contribute in myriad ways to a pro-growth glycolytic metabolic programme, by synchronizing proliferation rates with O 2 availability 2, 7 . Initially identified by its ability to regulate the erythropoietin gene (EPO), HIF1α was soon found to induce the expression of genes encoding glycolytic enzymes and glucose transporters 8, 9 , implicating HIF1α as an important contributor to the Warburg effect. By contrast and surprisingly, HIF2α complexes do not generally induce the expression of glycolytic enzyme genes regulated by HIF1α, but may achieve similar effects indirectly by enhancing the activity of MYC or other factors that also promote glycolysis 10 . In addition to increasing glycolytic activity, suppressing the production of reactive oxygen species (ROS) by the mitochondrial electron transport chain (ETC) seems to be a fundamental function of HIFs 11, 12 . Mitochondrial ROS levels paradoxically increase under hypoxic conditions and have been proposed to contribute to HIF α-subunits stabilization, although controversy on this point persists [13] [14] [15] . Recently, RAS-driven redox stress was reported to cause EGLN1 (also known as HIF prolyl hydroxylase 2, PHD2) protein dimerization through disulfide bond formation, inactivating the enzyme and stabilizing HIF α-subunits 16 . However, it should be noted that RAS was overexpressed in these studies, and whether physiological RAS levels would also cause PHD2 dimerization remains unclear. Whether induced by hypoxia or oncogenic signalling (for example, via activating mutations in RAS), HIFs suppress oxidative stress through various mechanisms: for example, HIF1α induces the expression of pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates and inhibits mitochondrial pyruvate dehydrogenase (PDH) 11, 12 . PDH converts glycolytic pyruvate into mitochondrial NADH and acetyl-CoA, thereby promoting oxidative mitochondrial metabolism. Inhibiting HIFmediated PDK1 expression increases mitochondrial NADH levels, flux through the ETC and formation of toxic ROS. Intriguingly, breast cancer cells require HIF1α-dependent PDK1 expression for efficient metastatic colonization of the liver, as opposed to colonization of bone or lung 17 . Liver-metastatic breast cancer cells are characterized by increased conversion of glucosederived pyruvate into lactate, and decreased mitochondrial metabolism. Moreover, human liver meta static lesions from patients with breast cancer exhibit increased PDK1 levels relative to other organ sites 17 . HIF1α also directly regulates the expression of the enzyme lactate dehydrogenase A (LDHA, which converts glycolytic pyruvate into lactate) and the mono carboxylate transporter 4 (MCT4) cell surface transporter, which mediates efflux of lactate from the cell 18 . Together, LDHA and MCT4 direct pyruvate away from oxidative metabolism, whereas LDHA inhibition increases intracellular ROS levels and redox stress.
HIF1α also alters mitochondrial metabolism indirectly, in part by stimulating the replacement of the cytochrome c oxidase subunit COX4-1 with COX4-2, which transfers electrons to O 2 more efficiently under hypoxic conditions, thereby lowering ROS levels 19 . Similarly, HIF1α-induced expression of the NADH dehydrogenase NDUFA4L2 inhibits ETC complex I activity and reduces O 2 consumption and ROS production 20 . Moreover, HIF1α inhibits MYC-dependent mitochondrial biogenesis though multiple complex processes 21, 22 , and reduces mitochondrial number by inducing the expression of BCL-2/adenovirus E1B 1 kDa protein-interacting protein 3 (BNIP3), which promotes mitophagy 7 . A related mechanism was recently reported for HIF2α, which promotes selective autophagy of peroxisomes in clear cell renal cell carcinoma (ccRCC) cells that are deficient in the Von Hippel-Lindau disease tumour suppressor protein (pVHL) 23 . Peroxisomes have a key role in cholesterol and bile acid synthesis and lipid degradation, generating large amounts of ROS in liver and other tissues, although the degree to which selective HIF-mediated peroxisome autophagy regulates cancer cell metabolism is as yet unknown.
The antioxidant glutathione is crucial to maintaining intracellular redox balance, and its synthesis requires NADPH generated in the oxidative pentose phosphate pathway (PPP). Hypoxia promotes PPP activity, in part Nature Reviews | Cancer ). Factor inhibiting hypoxia-inducible factor (FIH) hydroxylates an asparagine residue, inhibiting HIFα recruitment of p300-CBP cofactors. Of note, the precise contributions of ascorbate and iron to normoxic PHD2 enzymology are still under active investigation (see text). b | Under hypoxic conditions, HIF α-subunits are not hydroxylated and instead translocate to the nucleus where they bind to their constitutively expressed partner aryl hydrocarbon receptor nuclear translocator 1 (ARNT1). p300 and CBP serve as transcriptional cofactors. HIFα-ARNT recognizes hypoxic response elements (HREs) throughout the genome and promotes the transcription of hundreds of genes involved in cellular adaptations to hypoxic stress. Although HIF1α and HIF2α recognize the same HRE, they clearly promote the expression of mostly non-overlapping genes in certain contexts.
Gluconeogenesis
The reverse pathway in central carbon metabolism (relative to glycolysis) in which glucose is generated from precursors, and maintained as free glucose or converted into storage depots such as glycogen.
by inducing O-GlcNAcylation of glucose-6-phosphate dehydrogenase (G6PD), the first committed step in the PPP 24 . Interestingly, phosphofructokinase (PFK) O-GlcNAcylation inhibits PPP activity and also redirects glycolytic carbon into the pathway 25 . It is intriguing that O-GlcNAcylation of multiple enzymes is associated with increased PPP activity, although the mechanisms by which hypoxia and (possibly) HIF subunits contribute to these effects remain to be determined. HIF has also been reported to promote mitochondrial localization of the p53 target TP53-induced glycolysis and apoptosis regulator (TIGAR), which functions as a fructose 2,6-bisphosphatase, resulting in elevated hexokinase 2 activity and increased PPP flux 26 . Finally, hypoxia redirects glucose towards glycogen accumulation 27 , which provides glucose to the PPP. Glycogen synthase, muscle (GYS1) expression is rapidly induced by hypoxia, followed by a subsequent increase in glycogen phosphorylase, liver (PYGL) expression, which is required for glycogen catabolism. Interfering with PYGL expression correlates with increased ROS accumulation and p53-dependent senescence 27 . As many oncogenic pathways promote glycolysis (BCR-ABL, AKT, MYC, PTEN and others), through both HIF-dependent and HIF-independent means, the ability of HIF to modulate carbon flow and limit damaging ROS production may prove to be its most crucial metabolic function in cancer cells, irrespective of oncogenic context. HIF regulation by metabolic enzymes. Collectively, the data described above support a model in which HIF subunits are activated by hypoxia or oncogenic signalling (for example, downstream of mTORC1) to alter the expression of metabolic enzymes, thereby redirecting carbon flow and modulating ROS levels in cancer cells. Interestingly, recent evidence indicates that some of these same enzymes feedback-regulate HIF complexes through direct physical interaction. For example, HIF1α binds to and stimulates the expression of the pyruvate kinase M gene (PKM) 28 , which encodes alternatively spliced mRNAs encoding PKM1 and PKM2 isoforms. Extensive work has demonstrated that PKM2 is preferentially expressed in cancer (and rapidly dividing normal) cells, and has lower enzymatic activity than PKM1, thereby reducing pyruvate production and redirecting glycolytic carbon to biosynthetic pathways to support cell growth 6 . Semenza and colleagues 28 reported that PKM2, but not PKM1, physically binds to HIF1α, promotes its recruitment to hypoxia-response elements (HREs) and stimulates HIF transcriptional activity. Remarkably, this effect requires PHD3, which seems to hydroxylate specific proline residues on PKM2. A similar relationship was observed in macrophages, where lipopolysaccharide (LPS) stimulation induces PKM2 expression, which then forms a complex with HIF1α to mediate a switch from oxidative metabolism to a highly glycolytic programme in which glucose is not fully oxidized by the mitochondria, but is converted into lactate 29 . Furthermore, PKM2 promotes HIF1α-dependent interleukin 1β (IL-1β) secretion 29 . Although the precise role of PKM2 in tumour growth and progression is still unclear [30] [31] [32] [33] , it remains the subject of active investigation.
Both HIF1α and HIF2α also seem to interact physically with fructose-1,6-bisphosphatase 1 (FBP1), which cata lyses the first committed step in gluconeogenesis in liver and kidney tissue and is encoded by FBP1, a direct HIF1α target gene 34 . Metabolomic analyses of human ccRCC cells indicate that intermediates in the gluconeogenic pathway are significantly repressed rela tive to normal kidney tissue 34 . Some of these effects may be explained by loss of FBP1 enzymatic activity and consequent routing of carbon towards glucose catabolism -thereby opposing elevated gluconeogenic flux -as expression of FBP1 and other key gluconeogenic enzymes (that is, the glucose-6-phosphatase cata lytic subunit) is greatly reduced in ccRCCs, with FBP1 depleted in more than 1,000 samples tested to date. Surprisingly, however, a mutant and catalytically inert form of FBP1 also suppresses ccRCC growth in a HIF-dependent manner. Li and colleagues 34 demonstrated that FBP1 assembles with chromatin-bound HIF complexes and inhibits their activity through binding to a previously described, but poorly understood, negative regulatory region carboxyl-terminal to the HIF amino-terminal transactivation domain (TAD). Silencing FBP1 expression therefore results in elevated HIF activity, with consequent effects on glycolysis, PPP flux and proliferation, and seems to be a crucial step in ccRCC aetiology. These two examples indicate that at least some HIF-regulated enzymes can interact directly with HIF proteins to modulate their function through positive and negative feedback loops. The degree to which this mechanism extends to other HIF-regulated metabolic enzymes is currently under active investigation.
HIF activation by metabolites. Increasing evidence reveals that HIFα stabilization and activity is controlled indirectly by tricarboxylic acid (TCA) cycle intermediates, and contributes to cancer cell metabolism. For example, mutations in genes encoding fumarate hydratase (FH) or succinate dehydrogenase (SDH) are associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) or hereditary paragangliomapheochomocytoma syndrome, respectively 35, 36 . Succinate and fumarate accumulate to high levels in these tumours and can increase HIF1α levels, and HIF target gene expression, in part by competitive inhibition of 2OG-dependent PHD enzymes 37, 38 . The degree to which succinate and fumarate and other TCA cycle intermediates regulate PHD enzymes (and factor inhibiting hypoxia-inducible factor, FIH) activity in other tumour types is unclear, but these observations indicate that the relative levels of the canonical substrates (2OG, ascorbate and Fe 2+ ) versus structurally similar compounds can influence HIF activity. It is also interesting that PHD and FIH enzymes seem to be differentially responsive to inhibition by fumarate, citrate and ROS 39, 40 . It is also clear that increased levels of fumarate or succinate (or other intermediates) have HIF-independent roles in cancer cells. For example, mice with engineered inactivating FH mutations develop renal cysts, and whereas HIFs seem to be dispensable for cyst formation, antioxidant signalling by nuclear factor erythroid 2-related factor 2 (encoded by Nrf2) has a crucial Anaplerosis An intracellular process whereby tricarboxylic acid (TCA) cycle intermediates are replenished when they become limiting; for example, when entry of glucose-derived carbons is insufficient to maintain the mitochondrial TCA cycle, glutamine-derived carbons can replenish the pathway, maintaining homeostasis.
role 41 . Moreover, PHD and FIH enzymes are part of a much larger (≥70) group of 2OG-dependent dioxygenases that control epigenetic states, including DNA, RNA and histone demethylases (such as the methylcytosine dioxygenases TET family enzymes, α-ketoglutaratedependent dioxygen ase (FTO) and Jumonji enzymes) 42 . Interest ingly, FH and SDH loss is associated with increased DNA and histone methylation in multiple cancer cell types 42 . Recently, fumarate and succinate were shown to be direct inhibitors of TET1 and TET2 enzymes, resulting in DNA hypermethylation and reduced HIF target gene expression 43 . Finally, mutations in genes encoding the isocitrate dehydrogenases IDH1 and IDH2 led to accumulation of the novel 'onco metabolite' 2-hydroxyglutarate (2HG), which inhibits TET2 and lysine-specific demethylase 4A (KDM4A, a Jumonji family histone demethylase also known as JMJD2A) and alters epigenetic gene regulation in gliomas, acute myeloid leukaemia and other tumour types 44, 45 . 2HG has been reported to activate PHD2 and reduce HIF1α protein accumulation in an enantiomer-specific manner 46 , although these data remain controversial 47 . HIF activity is also regulated by intracellular Fe 2+ , as ascorbate regulates Fe 2+ availability at the PHD catalytic centre, in certain contexts [48] [49] [50] . Increased cellular ascorbate levels correlate with elevated PHD hydroxylase activity and reduced HIF accumulation, and are associated with a less aggressive phenotype in endometrial 51 and colorectal 52 cancers. In another example of reciprocal regulation, HIF2α has a primary role in iron absorption and homeostasis 53, 54 , in part by regulating the expression of the iron transporter DMT1 (also known as natural resistance-associated macrophage protein 2, NRAMP2), cytochrome b reductase 1 (encoded by CYBRD1 and also known as duodenal ferric reductase, DCYTB) and ferroportin. HIF2α accumulation itself is regulated by iron regulatory proteins (IRPs) that bind to HIF2A mRNA to increase its translation in an Fe 2+ -dependent manner 55 . This arrangement seems to coordinate erythropoiesis by matching HIF2α-dependent EPO production 56, 57 with iron availability 53, 54 . To what degree Fe 2+ availability, transport and oxidation state regulate HIF responses in cancer cells, and alter their redox and metabolic states, is an exciting area for future investigation.
O 2 availability and intracellular reactions
Compared with normal cells, malignant cells exhibit significant metabolic alterations regarding crucial nutrients and substrates, such as glucose, glutamine and fatty acids, and the hypoxic tumour microenvironment has a central role in their uptake and use.
Metabolic reprogramming in hypoxic cells. As described above, HIFs mediate many adaptive responses to reduced O 2 availability, including but not limited to enhanced glucose and glutamine uptake, glycolysis and glycogen synthesis, and reduced pyruvate catabolism and O 2 consumption by mitochondria 1 . For example, O 2 deprivation creates a deficit of glucose-derived acetylCoA needed for lipid synthesis, owing to elevated PDK1 activity inhibiting the conversion of pyruvate into acetylCoA for entry into the TCA cycle 6 . This could result in decreased levels of TCA cycle intermediates needed for multiple biosynthetic reactions. Fatty acid generation begins with cleavage of TCA cycle-derived citrate into acetyl-CoA and oxaloacetate (FIG. 2) , and subsequent carboxylation of acetyl-CoA to produce malonyl-CoA, which is further assembled into long-chain fatty acids by fatty acid synthase (FASN). In addition to supplying citrate, the TCA cycle also generates precursors for the synthesis of non-essential amino acids such as aspartate and asparagine. Thus, to maintain citrate and amino acid biosynthesis, their production is balanced by the ultimate conversion of glutamine into 2OG during TCA cycle anaplerosis 6 . Glutamine-derived 2OG generates oxaloacetate and malate for the production of citrate as well as NADPH via malic enzyme 1 (ME1), independently of glucose entry into the cycle. When hypoxia creates a deficit of glucose-derived acetyl-CoA, 'reductive carboxylation' of 2OG reverses a section of the TCA cycle, converting mitochondrial 2OG into citrate, which enters the cytosol to generate acetyl-CoA for fatty acid and cholesterol biosynthesis [58] [59] [60] . Hypoxic cells therefore exhibit increased rates of glutamine uptake to compensate for decreased entry of glucose-derived carbons into the mitochondrion. Moreover, hypoxia shifts glutamine metabolism from oxidation to reductive carboxylation by HIF1α-mediated turnover of the E1 subunit 2OG dehydrogenase (via SIAH2 ubiquitylation), which is required for more typical conversion of 2OG into succinate 61 . Recently, extracellular acetate has been shown to be used by some cancer cells (such as glioblastoma or breast cancer brain metastases) as an alternative source of acetyl-CoA needed for anabolic processes, such as de novo fatty acid synthesis [62] [63] [64] . Here, imported acetate is converted into acetyl-CoA by acetyl-CoA synthetase 2 (ACSS2). As such, decreased cytosolic acetyl-CoA levels imposed by hypoxia can be replenished by increasing the catabolism of free acetate from plasma and interstitial fluid, in addition to TCA cycle 2OG reductive carboxylation when O 2 is limiting. Although HIF amplifies many of these metabolic adaptations by upregulating PDK1 and 2OG dehydrogenase, it should be noted that such metabolic adaptations to hypoxia can also occur in HIF-deficient cells 11, 12 . Thus, changes in intracellular biochemical pathways downstream of low O 2 are both HIF dependent and HIF independent.
Additional hypoxic influences on lipid homeostasis. In addition to increased demand for nucleotides, amino acids and reducing equivalents such as NADPH, proliferating cancer cells require abundant pools of multiple lipid species for membrane synthesis, lipid-based signalling reactions and other processes 65 . Fatty acids are derived from endogenous citrate (and sometimes exo genous acetate) or taken up from extracellular sources. Elevated rates of lipid synthesis typically occur through increased expression of multiple lipogenic enzymes, for example, downstream of mTORC1 (REFS 66, 67) . Cancer cell survival depends on enhanced lipid production, and FASN overexpression is strongly correlated with the progression of breast cancer and other malignancies 68, 69 . Fatty acids can be incorporated into membranes as phospholipids, stored in lipid droplets or used for the synthesis of signalling lipids, such as sphingosine 1-phosphate 65 . They can also be catabolized by mitochondrial β-oxidation as an alternative means of ATP production when glucose and glutamine are limiting. The requirement for fatty acids and cholesterol is met largely by synthesis from glucose-derived carbon, but can also depend on fatty acid uptake, especially in hypoxic conditions. To obtain free fatty acids from plasma, chylomicron tri glycerides and low-density lipoprotein particles are hydrolysed by lipoprotein lipase and imported via the CD36 fatty acid channel protein, among other mechanisms 70 . Multiple cancer cells exhibiting constitutive mTORC1 activity (owing to deficiency in the tumour suppressor tuberin, encoded by TSC2, or other oncogenic events) die in ischaemic conditions in which O 2 , glucose and blood-borne nutrients (serum) are limiting, owing specifically to decreased pools of unsaturated lipids 71 . This programmed cell death occurs because the desaturation by stearoyl-CoA desaturases (SCDs) of de novo synthesized fatty acids is an O 2 -consuming biochemical reaction. Oxygen limitation inhibits these enzymatic reactions, rendering cells dependent on exo genous lipids to avoid a crucial unsaturated lipid deficiency, causing cell death downstream of ER stress and a toxic unfolded protein response (UPR). Ratios of cellular unsaturated to saturated lipid and cholesterol availability are necessary for membrane homeostasis of the ER and other organelles 72 . Furthermore, the ER provides an important platform for the biosynthesis of both protein and lipids 65 . If oncogenic drivers of anabolic metabolism result in protein overproduction while the ER is unable to expand owing to lack of membrane fluidity, a terminal UPR is engaged followed by cell death 71 . Along these lines, hypoxic cells exhibit increased uptake of lyso phospho lipids, in particular, Nature Reviews | Cancer TETs promote the removal of methyl groups from 5-methylcytosine residues in DNA, altering gene expression in leukaemias and solid tumours of the brain and cartilage. However, cells harbouring wild-type IDHs produce elevated levels of l(S)-2-hydroxyglutarate (l-2HG, the enantiomer of d-2HG) under hypoxia. Recent work from two independent research groups has shown that l-2HG produced in hypoxic glioblastoma, neuroblastoma and renal carcinoma cells as well as blood vessel components is largely HIF independent and has several downstream effects 79, 80 .
Intlekofer et al. 79 demonstrated that elevated l-2HG levels result in increased methylation of histone repressive marks (such as histone 3 lysine 9 (H3K9) and K27) in response to hypoxia, owing to inhibition of the epi genetic modifier histone demethylase KDM4C. Oldham et al. 80 showed that hypoxia specifically increases l-2HG in additional cell types, such as pulmonary endothelial and smooth muscle cells, maintaining cellular and mitochondrial redox balance. Surprisingly, the source of l-2HG is not IDH enzymatic activity, but malate dehydrogenase (MDH) and LDHA metabolism. In cancer cells, l-2HG arises via promiscuous substrate usage by LDHA, with some input from MDH1 and MDH2. LDHA and MDH reduction of 2OG to l-2HG is NADH dependent, and most of the 2OG is derived from imported glutamine in hypoxic cells. However, malignant cells are more dependent on LDHA for l-2HG production, whereas endothelial and smooth muscle cells are more reliant on the MDHs. The relevant roles of these metabolic enzymes in distinct cell types (for example, normal versus cancerous cells) remain unclear. Nevertheless, these findings have therapeutic implications for hypoxic tumours, as glutamine catabolism can be inhibited by small-molecule inhibitors of glutaminase 81 . Moreover, unbiased metabolomics identified elevated l-2HG in ccRCC, owing to reduced expression of l-2HG dehydrogenase 82 . Restored l-2HG dehydrogenase expression increased 5-methylcytosine accumulation and suppressed renal tumour growth. Overall, on the basis of these findings, glutamine not only contributes to the biosynthesis of cholesterol and fatty acids, but is also crucial for redox homeostasis and maintenance of the epigenome in O 2 -limited cells.
In addition to HIF-independent l-2HG production by hypoxic cells, the accumulation of lactate can stabilize NDRG family member 3 (NDRG3) by inhibiting the PHD2-pVHL degradation machinery in an O 2 -regulated fashion 83 . Here, NDRG3 (a novel pVHL substrate) binds directly to excess lactate, which builds up during hypoxia, inhibiting its ubiquitylation and proteasomal degradation by disrupting the NDRG3-pVHL interaction. Stabilized NDRG3 protein then binds to RAF, activating the RAF-ERK pathway to promote angiogenesis, breast cancer cell proliferation and tumour growth. NDRG3 is also highly induced in other cancer cell types when O 2 levels decline 83 . As lactate is a glycolytic end product, NDRG3 accumulation is indirectly dependent on HIF1α, which regulates LDHA expression in hypoxic cells. Nevertheless, these findings imply that the PHD2-pVHL system can regulate both HIF-dependent and HIF-independent responses downstream of low O 2 , and they raise the question of whether other proteins respond to lactate build-up during prolonged hypoxia.
Are 2OG-dependent dioxygenases influenced by O 2 levels in the microenvironment? The human genome encodes an estimated 60-70 O 2 -consuming, Fe2 + -dependent and 2OG-dependent dioxygenases with diverse biochemical roles involving oxidative reactions associated with fatty acid metabolism, carnitine biosynthesis and phytanic acid catabolism 84 . However, the reactions identified thus far involve mostly hydroxylations and demethylation of N-methylated groups in proteins and nucleic acids, via their initial hydroxylation (FIG. 3) . At first, it was suggested that the HIF hydroxylases (such as PHDs and FIH) have special biochemical properties -such as O 2 -sensing properties -that set them apart from other 2OG dioxygenases 85 . Specifically, the K m O 2 (oxygen concentration required for half-maximal catalytic rate) for PHD2 was initially reported to be 200-250 μm, which is unusually high for this class of enzyme 85 . This could make HIF hydroxylases particularly sensitive to fluctuations in O 2 concentrations detected in both physiological and pathological situations. However, subsequent biochemically superior assays (in which larger HIFα fragments were used as substrates as opposed to short polypeptides), determined that PHDs actually have lower K m O 2 values, that is, approximately 100 μm, which are similar to those reported for other 2OG dioxygenases 86 . Therefore, many of the broader 2OG-dependent enzyme family members reside at physiological tissue pO 2 levels (where pO 2 refers to the partial pressure of oxygen in a hypothetical tissue volume) predicted to be below even the lower K m O 2 estimates, whereas intracellular oxygen gradients can create further decreased O 2 levels. Of note, physiological tissue pO 2 levels vary extensively from 7.2 mm (7,200 μm) Hg, or 1% pO 2 , to 108 mm (1.08 × 10 5 μm) Hg or 15% pO 2 . This makes many of the 2OG dioxygenases potential oxygen sensors, if their catalytic activity is rate limiting for the overall biochemical pathway in which they function.
It has also been suggested that the 2OG dioxygenases (especially the PHDs) simultaneously sense changes in intracellular concentrations of oxygen and TCA cycle intermediates, namely 2OG itself 38, 87 . The use of O 2 and 2OG in the hydroxylation reaction would therefore link hypoxic and metabolic signalling in a very appealing way. However, it remains unclear whether intracellular 2OG levels ever become limiting for the HIFs and other hydroxylases 3 . Instead, the availability of Fe 2+ as a cofactor may be more variable and therefore important for modulating the enzymatic activity of dioxygenases, enabling them to detect changes in cellular iron levels as well as redox signals 85 . As stated above, there is substantial evidence that the PHDs and FIH1 are inhibited by oxidant stress. Moreover, although 2OG abundance may not be a limiting factor for dioxygenase activity, other TCA cycle metabolites (fumarate and succinate) when overproduced clearly serve as competitive inhibitors for the hydroxylase reactions 37, 38, 88 . Post-translational hydroxylation of prolyl and lysyl residues by 2OG dioxygenases was first identified in collagen maturation, followed by the prolyl and asparaginyl hydroxylation of HIFs 84 . The ability of 2OG dioxygenases to catalyse N-demethylation (via hydroxylation) of N-methylated histone lysyl residues (especially the H3 amino-terminal tail) and 5-methylcytosine links this family of enzymes to epigenetic regulation. If the K m O 2 for histone and nucleic acid hydroxylases proves to be similar to those measured for the PHDs, it suggests that steep O 2 gradients, fluctuating O 2 availability and changes in fumarate and succinate concentrations, all of which typically occur in solid tumour micro environments, may impart more durable changes in the epi genome of cancer cells, along with influencing the HIF pathway and deposition of extracellular matrix.
Hypoxia, mTOR and calcium signalling
In addition to the HIF pathway, cells maintain their meta bolic homeostasis through independent, but closely linked molecular signalling networks. One major sensor of nutrient availability is the mTOR pathway 89 . In brief, mTOR integrates energy and nutrient sensing inputs by the cell and controls cellular growth and proliferation (TABLE 1) . In mammals, there are two separate mTOR catalytic units, mTORC1 and mTORC2. Both complexes share a catalytic mTOR subunit, mLST8, DEPTOR and Tti1-Tel2 complex. mTORC1 also contains regulatory-associated protein of mTOR (RAPTOR) and PRAS40, whereas mTORC2 contains rapamycininsensitive companion of mTOR (RICTOR), mSIN1 (also known as MAPKAP1) and PROTOR1 and PROTOR2 (also known as, respectively, PRR5 and PRR5L) proteins. When mTORC1 is activated under energy-or nutrient-replete conditions, it enhances cell growth and protein synthesis through phosphorylation of ribosomal S6 kinase 1 (S6K1), and the eukaryotic translation initiation factor 4E binding protein (4EBP1). By contrast, mTORC2 signalling, although much less understood, seems to be insensitive to nutrient conditions but does respond to growth factors. One major output of mTORC2 signalling is phosphorylation and activation of AKT at Ser473, whose activity can ultimately lead to mTORC1 activation 90 . It is not surprising that cancer cells co-opt mTOR's pro-growth outputs, through modulation of either direct (such as loss of TP53 or PTEN) or indirect (activation of AKT or RAS) regulators of the pathway 6, 91 . Numerous internal and external stresses can alter mTOR signalling in tumour cells, including O 2 availability. One of the first connections identified between hypoxia and mTOR demonstrated that AMP-activated protein kinase (AMPK) phosphorylates TSC2 and inhibits mTORC1 in response to low-energy or hypoxic states 92 . Furthermore, mTORC1 promotes glycolysis by enhancing both the transcription and translation of HIF1α (REFS 66, 93) . Loss of liver kinase B (LKB1, also known as STK11), the upstream kinase of AMPK, increases HIF1α accumulation via increased ROS as well as mTORC1 Nature Reviews | Cancer Key activators (purple) and inhibitors (red) of the mTOR complex 1 (mTORC1) and mTORC2 pathways are shown. A diverse array of extracellular inputs, such as insulin, growth factors and amino acids can promote mTOR activity. These signals lead to the inactivation of the TSC1-TSC2 tumour suppressor complex, an upstream inhibitor of mTORC1. They can also activate mTORC2 through phosphatidylinositol trisphosphate (PIP3) and AKT. For mTORC1, the main outputs are increased ribosomal biogenesis, CAP-dependent mRNA translation and a series of anabolic pathways, such as purine, pyrimidine and lipid synthesis. mTORC2 is associated with pro-survival activity, as well as modification of the cytoskeleton and other metabolic adaptations. Hypoxia can inhibit mTORC1 through regulation of DNA damage response 1 (REDD1) or REDD2, which are hypoxia-inducible factor-1α (HIF1α) target genes. Additionally, hypoxia leads to energy deficiency (elevated AMP/ATP ratio), which can inhibit mTORC1 through AMP-activated protein kinase (AMPK). Interestingly, HIF2α enhances mTORC2 activity by promoting amino acid import through the transporter SLC7A5. It should be noted that REDD1 can be phosphorylated and activated ahead of increased abundance downstream of HIF1α, so it is itself an O 2 sensor. DEPTOR, DEP domain-containing mTOR-interacting protein; IGF, insulin-like growth factor; IRS1, insulin receptor substrate 1; PDK1, 3-phosphoinositidedependent protein kinase 1; RAPTOR, regulatory-associated protein of mTOR; RICTOR, rapamycin-insensitive companion of mTOR; S6K1, ribosomal S6 kinase 1. activity 94 . However, HIF can also provide feedback inhibition of the mTORC1 pathway in an AMPK-independent manner, through its target gene regulation of DNA damage response 1 (REDD1) 95, 96 . The isoform REDD2 is also hypoxically induced and inhibits mTORC1; however, its expression is restricted to certain tissues 97, 98 . Interestingly, HIF2α affects mTORC1 in a manner that is independent of HIF1α (REF. 99 ). In the context of pVHL-deficient mouse tissue and RCC cell lines, HIF2α promotes mTORC1 activity by increasing the expression of the amino acid transporter SLC7A5, which functions as an antiporter by effluxing l-glutamine while importing l-leucine. One theory for this differential effect on mTORC1 postulates that distinct kinetics of HIF1α versus HIF2α stabilization are responsible for these observations. HIF2α stabilization occurs at higher O 2 concentrations over longer periods of hypoxia 100 , and cells may therefore require some basal activity of mTOR to survive this longer-term stress. By contrast, HIF1α is stabilized at lower O 2 levels but its induction is short-lived compared with HIF2α, and therefore inhibiting mTORC1 acutely might be more beneficial for cell survival 100 .
In addition to the above-mentioned inputs that regulate mTOR, calcium availability and its downstream signalling also promote mTORC1 activity. Amino acids, as critical stimulators of mTORC1 activity, induce a rise in intracellular calcium concentrations, triggering mTORC1 activation through calmodulin (CaM) and the lipid kinase VPS34 (also known as phosphatidylinositol 3-kinase cata lytic subunit type 3, PIK3C3) 101, 102 . In addition, calcium can regulate mTORC1 through Ca 2+ /calmodulin-dependent protein kinase type II (CaMKII) 103, 104 . Phosphorylation of CaMKII leads to activation of mTORC1, although the specific mechanisms are not well defined. Nakazawa et al. 105 have recently determined that HIF2α can act upstream of Ca 2+ effects on mTORC1, in the setting of soft-tissue sarcomas; however, how broadly applicable this is to other tumour types remains to be determined.
Hypoxic regulation of autophagy
Autophagy is a cellular process whereby cells engulf and degrade proteins, organelles and cytoplasm, recycling them to provide themselves with substrates for energy production and to sustain cellular metabolism 106 . Under various stress conditions, including nutrient or growth factor deprivation, cytotoxic agents and low O 2 availability, cells activate autophagy. Depending on the cellular context and type of cancer, autophagy can either promote or inhibit tumour growth 107, 108 . In malignant cells, stress-induced autophagy seems to be protective against adverse microenvironmental stresses and cytotoxic therapies. In healthy tissues, autophagy mediates tumour-suppressive functions by preventing the accumulation of cellular stressors such as uncoupled mitochondria, peroxisomes and damaged ER.
Several molecular sensors are responsible for detecting and translating such homeostatic perturbations into a pro-autophagy signal (FIG. 4) . For example, AMPK, which responds to increases in cellular AMP/ATP ratio, directly phosphorylates ULK1, an autophagy initiation kinase, while also inhibiting mTORC1 (REF. 109 ). Misfolded proteins in the ER can activate autophagy through PERK (also known as eIF2αK3) as well 110 . Another complex that activates autophagy is VPS34-p150-Beclin 1, in which Beclin 1 autophagic function is inhibited by the anti-apoptotic protein BCL-2 (REFS 111, 112) . Once the pro-autophagy signal is activated, an autophagosome (a double-membraned microvesicle) is initiated and elongated by other proteins, such as members of the ATG family (for example, ATG5, ATG7, ATG12 and ATG16) and LC3 conjugated to phosphatidylethanolamine (PE) (LC3II), which ultimately close the autophagosome around the targets to be degraded 106 . The autophagosome subsequently fuses to a lysosome, creating an autolysosome, which ultimately degrades the contents held inside.
Several chemical inhibitors of autophagy block different steps along the autolysosome formation pathway 113 . One of the best characterized is chloroquine (or hydroxychloroquine), which was initially clinically approved as an antimalarial treatment 114 . Chloroquine is a lysosomotropic agent, and accumulates in acidic compartments such as endosomes and lysosomes. There, it prevents acidification of the endosome, which in turn inhibits lyso somal enzymes that require low pH to function. This effect inhibits fusion of the lysosome with the autophagosome, thus preventing degradation of the products inside. Bafilomycin A, another commonly used autophagy inhibitor, inhibits autophagy at a similar step in the pathway 115 . Additionally, more specific inhibitors of autophagy are under investigation (for example, ATG7 inhibitors), but are still at the preclinical stage of development 113 . Beyond the prolyl hydroxylases (PHDs) and factor inhibiting hypoxia-inducible factor (FIH), 60-70 2-oxoglutarate (2OG; also known as α-ketoglutarate)-dependent dioxygenases have either been biochemically confirmed or predicted based on sequencing of the human genome 84 . Their relative K m O 2 for molecular oxygen and dependence on Fe 2+ indicate that their activities could increase or decrease, based on pO 2 levels and concentrations of succinate, fumarate and l-2-hydroxyglutarate (l-2HG) accumulation in the tumour microenvironment. As shown, they have various enzymatic functions in cells that affect the extracellular matrix, methylation status of histones and nucleic acids and components of the translation machinery, along with pivotal roles in maintaining oxygen homeostasis by hydroxylating hypoxia-inducible factor-α (HIFα) subunits. JMJ-KDMs, Jumonji family of histone demethylases; PLODs, procollagen-lysine, 2-oxoglutarate 5-dioxygenases. Nature Reviews | Cancer Nature Reviews | Cancer Ribosome Polypeptide Nature Reviews | Cancer
Protein
Although O 2 availability affects mTORC1, one of the main suppressors of autophagy as described above, it also affects autophagy regulators directly. For example, BNIP3 and BNIP3-like (BNIP3L; also known as NIX) are upregulated by HIF1α (REF. 116 ). Whereas these proteins are implicated in apoptosis, it has also been shown that they disrupt BCL-2-Beclin 1 complexes, freeing Beclin 1 to activate autophagy in hypoxic cells. BNIP3 and BNIP3L have also been shown to be important in mitophagy 113 .
Targeting oxygen-sensing pathways As outlined above, the HIFs have important roles in promoting tumour growth and progression through metabolic reprogramming, making them an attractive therapeutic target in cancer 117 . However, inhibiting these transcription factors specifically has been challenging. In the past, drugs have been developed that inhibit the HIFα subunits, but with little specificity between the two sub units 118 . These drugs vary in their specific mechanisms of action. For example, some inhibitors of HIF block transcriptional activity and DNA binding by inhibiting dimerization of HIFα with aryl hydrocarbon receptor nuclear translocator (ARNT) or by inhibiting p300 recruitment. Other HIF inhibitory drugs indirectly affect HIF1α translation, often through pathways that impinge on mTORC1 or epidermal growth factor receptor (EGFR)-PI3K signalling. The full list of HIF inhibitors currently under clinical investigation are reviewed elsewhere (see REF. 118) but are still an area of active investigation.
Relatively recently, a highly selective HIF2α inhibitor has been developed that specifically interrupts HIF2α and ARNT heterodimerization 119 . This drug targets a large hydrophobic cavity within HIF2α. The analogous pocket in HIF1α is smaller, giving the compound its HIFα isoform specificity. It has promising therapeutic potential for treating cancers such as ccRCC, for which it has been demonstrated that HIF2α is particularly important for disease progression, whereas HIF1α is actually a tumour suppressor 3 . Recently, the crystal structures of HIF1α-ARNT and HIF2α-ARNT heterodimers have been resolved, confirming the location at which the drug inhibits HIF2α-ARNT dimerization 120 . Interestingly, Wu and colleagues 120 show that the overall architecture of both HIF1α-ARNT and HIF2α-ARNT heterodimers is the same, with similar domains interacting at similar sites with ARNT. However, now that the structure of binding to the heterodimers has been established, new druggable sites beyond the hydrophobic pocket in HIF2α-ARNT may be elucidated. Moreover, selective degradation approaches in which targets are ubiquitylated via chemical linkers to E3 ligase machinery components could ultimately enable HIFs to be effectively inhibited in a broad range of cancers.
More recent approaches have used evofosfamide (previously known as TH-302), a pro-drug activated by hypoxic tumour microenvironments, as a means of treating pancreatic cancer [121] [122] [123] . Here, cytotoxic DNAalkylating agents are activated upon O 2 depletion in malignant pancreatic lesions, in an effort to specifically target the most oxygen-limited sections of the Nature Reviews | Cancer in response to cellular stress. The autophagic pathway consists of several steps, including nucleation and sequestration of a phagophore, formation of an autophagosome and its fusion with a lysosome to form an autolysosome. Initiation and nucleation of the autophagophore begins when several proteins, including ULK1 and Beclin 1, are inhibited by mTOR complex 1 (mTORC1) and BCL-2 activity, respectively. BCL-2/adenovirus E1B 1 kDa protein-interacting protein 3 (BNIP3), a hypoxically induced protein, displaces Beclin 1 from BCL-2. After nucleation, several ATG proteins are involved in the conjugation of phosphatidylethanolamine (PE) to LC3, to form LC3II. LC3II is necessary for autophagic membrane expansion, recognition of autophagic cargo and the fusion of lysosomes to autophagosomes. Another hypoxically induced protein, BNIP3-like (BNIP3L), is involved in sequestering mitochondria to the autophagosome. p62 functions as an autophagy cargo receptor, which is ultimately degraded when the autolysosome forms. Severe hypoxia (<0.01% O 2 ) can also activate autophagy in a hypoxia-inducible factor (HIF)-independent mechanism through the unfolded protein response (UPR).
Once the autophagosome has formed, it fuses with a lysosome to generate an autolysosome, leading to the degradation of the products inside. Autophagy can also modulate HIF1α levels. Chaperone-mediated autophagy proteins heat shock cognate 71 kDa protein (HSC70) and lysosome-associated membrane glycoprotein 2A (LAMP2A) traffic HIF1α to lysosomes, where it is subsequently degraded. AMPK, AMP-activated protein kinase.
tumour beyond inhibiting HIF itself. The efficacy of this approach, and stratification of patients most likely to respond, are ongoing investigations in the clinic.
Concluding remarks
Overall, the influence of O 2 and nutrient availability on the metabolism of both malignant cells and stromal components of the tumour microenvironment is considerable and extends well beyond the pVHL-PHD2-HIF axis. Future efforts should reveal how other O 2 -regulated metabolic adaptations affect the cancer epigenome, cross-talk between cancer cells and recruited leukocytes, reactive fibroblasts and blood vessels, and local invasion and/or metastasis. All this integrated information will greatly accelerate the development of novel therapies targeting not only mutated cancer cells, but others, such as diploid T cells, B cells and macrophages and the extracellular matrix, to impart more durable responses to patients with numerous solid and haematological malignancies. As targeting genetically and epigenetically unstable cancer cells will probably result in acquired resistance over time, affecting stromal metabolism may be the best option to promote stable disease or remission. Finally, metabolic interventions could be combined with immunotherapeutic approaches, to treat a broad range of malignancies with diverse genetic or epigenetic alterations in the future.
